A heart and blood pressure drug for advanced lung cancer with high blood pressure
Part of Cancer, Heart & circulation, Lungs & breathing clinical trials.
This study tests whether a heart and blood pressure medication called ARNI can help people with advanced lung cancer who also have high blood pressure. It may help control blood pressure and possibly improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and under the age of 80.
- You have been diagnosed with advanced lung cancer (stage III or IV).
- You were diagnosed with high blood pressure before your lung cancer diagnosis.
- You are generally able to do daily activities without needing a lot of help (ECOG score 0 or 1).
- Your heart, liver, and kidneys are working well enough for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a blood pressure medication (an angiotensin receptor-neprilysin inhibitor, or ARNi) in adults with high blood pressure in the United Arab Emirates. It looks at how well the medicine works in real life, and may be an option if you are just starting treatment or already taking one blood pressure pill.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This study tests whether two blood pressure medications (nicardipine and nitroglycerin) affect how well your lungs exchange oxygen and remove carbon dioxide. It uses a special chest monitor to see if these drugs improve lung function during breathing machine support.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.